OBJECTIVE: To analyse 12-month response to GH treatment in a single-country cohort of hypopituitary adult patients with GH deficiency (GHD) in regards to health-related quality of life (HRQoL) and insulin-like growth factor-1 (IGF-1) compared with values from general population sample. Moreover, association between the response in HRQoL and the IGF-1 values in patients and in the background population was investigated. DESIGN: HRQoL was assessed by quality of life assessment of GH deficiency in adults (QoL-AGHDA) in 651 patients retrieved from the German KIMS (Pfizer International Metabolic Database) before and after 12 months of GH replacement and in a sample drawn from a cross-sectional study in Germany (n=2734). IGF-1 was measured in KIMS patients and in the population-based study with the same assay technique. RESULTS: In KIMS patients, mean QoL-AGHDA scores before GH replacement were 9.2+/-6.8 (8.7+/-6.8) in women (men) and in the general population sample 4.5+/-5.3 (4.3+/-5.0) in women (men). Mean differences in QoL-AGHDA scores were statistically significant for all age categories (P<0.05). The mean IGF-1 SDS of KIMS patients before GH replacement was -1.1+/-1.4 (-0.8+/-1.4) in women (men). After GH replacement, a significant increase of IGF-1 concentration and a significant decrease of QoL-AGHDA scores near to age- and gender-specific population-based values were observed. CONCLUSIONS: This study confirms an improvement in HRQoL and an increase of IGF-1 SDS in GH-replaced adults, which approximated the values of general population. However, there was no association between IGF-1 values and HRQoL assessment as one of the important treatment outcomes.
OBJECTIVE: To analyse 12-month response to GH treatment in a single-country cohort of hypopituitary adultpatients with GH deficiency (GHD) in regards to health-related quality of life (HRQoL) and insulin-like growth factor-1 (IGF-1) compared with values from general population sample. Moreover, association between the response in HRQoL and the IGF-1 values in patients and in the background population was investigated. DESIGN: HRQoL was assessed by quality of life assessment of GH deficiency in adults (QoL-AGHDA) in 651 patients retrieved from the German KIMS (Pfizer International Metabolic Database) before and after 12 months of GH replacement and in a sample drawn from a cross-sectional study in Germany (n=2734). IGF-1 was measured in KIMS patients and in the population-based study with the same assay technique. RESULTS: In KIMS patients, mean QoL-AGHDA scores before GH replacement were 9.2+/-6.8 (8.7+/-6.8) in women (men) and in the general population sample 4.5+/-5.3 (4.3+/-5.0) in women (men). Mean differences in QoL-AGHDA scores were statistically significant for all age categories (P<0.05). The mean IGF-1SDS of KIMS patients before GH replacement was -1.1+/-1.4 (-0.8+/-1.4) in women (men). After GH replacement, a significant increase of IGF-1 concentration and a significant decrease of QoL-AGHDA scores near to age- and gender-specific population-based values were observed. CONCLUSIONS: This study confirms an improvement in HRQoL and an increase of IGF-1SDS in GH-replaced adults, which approximated the values of general population. However, there was no association between IGF-1 values and HRQoL assessment as one of the important treatment outcomes.
Authors: Robert C Kaplan; Ann-Kristin Petersen; Ming-Huei Chen; Alexander Teumer; Nicole L Glazer; Angela Döring; Carolyn S P Lam; Nele Friedrich; Anne Newman; Martina Müller; Qiong Yang; Georg Homuth; Anne Cappola; Norman Klopp; Holly Smith; Florian Ernst; Bruce M Psaty; H-Erich Wichmann; Douglas B Sawyer; Reiner Biffar; Jerome I Rotter; Christian Gieger; Lisa S Sullivan; Henry Völzke; Kenneth Rice; Ariadni Spyroglou; Heyo K Kroemer; Y-D Ida Chen; Jenny Manolopoulou; Matthias Nauck; Howard D Strickler; Mark O Goodarzi; Martin Reincke; Michael N Pollak; Martin Bidlingmaier; Ramachandran S Vasan; Henri Wallaschofski Journal: Hum Mol Genet Date: 2011-01-07 Impact factor: 6.150
Authors: Lisa L Morselli; Arlet Nedeltcheva; Rachel Leproult; Karine Spiegel; Enio Martino; Jean-Jacques Legros; Roy E Weiss; Jean Mockel; Eve Van Cauter; Georges Copinschi Journal: Eur J Endocrinol Date: 2013-04-15 Impact factor: 6.664
Authors: Stephen P McKenna; Jeanette Wilburn; James Twiss; Sigrid R Crawford; Václav Hána; Malgorzata Karbownik-Lewinska; Vera Popovic; Mikulas Pura; Maria Koltowska-Häggström Journal: Health Qual Life Outcomes Date: 2011-08-02 Impact factor: 3.186
Authors: M P Kawa; I Stecewicz; K Piecyk; E Pius-Sadowska; E Paczkowska; D Rogińska; A Sobuś; K Łuczkowska; E Gawrych; E Petriczko; M Walczak; B Machaliński Journal: Endocrine Date: 2015-04-29 Impact factor: 3.633